How can physicians empathetically deliver a diagnosis that reflects the evolving landscape of Alzheimer's disease care: A scoping review. (PubMed, J Alzheimers Dis Rep) - Oct 16, 2026 - "The research landscape of AD has undergone a rapid transformation, marked by disease-modifying therapies such as lecanemab and donanemab. The scoping review found few studies on novel therapies' impact on diagnostic conversations and no formal guiding frameworks. This gap highlights the need to investigate physicians' approaches to discussing disease-modifying therapies for AD, which forms the basis of ongoing research."
Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Psychiatry
|
|
Asha Duhan; Stephen Post; Wei-Hsin Lu
|